However, another proteomic screening study of post-mortem AD brains found that both FABP3 and FABP7 levels were elevated in the brains of symptomatic AD patients compared to those of asymptomatic AD patients, with the increase of FABP7 being significantly higher than that of FABP3 (Johnson et al., 2018, 2020; Higginbotham et al., 2020; Hampel et al., 2021a; Rayaprolu et al., 2021; Wingo et al., 2021). This evidence concerns the gene FABP7 and Alzheimer disease.